Home > Boards > US Listed > Biotechs > Argenx SE (ARGX)

Efgartigimod is a first-in-class antibody fragment designed for

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
riche Member Profile
 
Followed By 1
Posts 29
Boards Moderated 0
Alias Born 12/15/10
160x600 placeholder
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 2/27/2020 6:20:26 AM
argenx reports full year 2019 financial results and provides fourth quarter business update GlobeNewswire Inc. - 2/27/2020 1:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 1:44:41 PM
argenx announces closing of global offering GlobeNewswire Inc. - 11/12/2019 4:00:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/8/2019 5:19:46 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/8/2019 5:15:58 PM
argenx announces full exercise of underwriters’ option to purchase additional ADSs GlobeNewswire Inc. - 11/8/2019 1:00:00 AM
argenx raises $484 million in gross proceeds in a global offering GlobeNewswire Inc. - 11/6/2019 10:45:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/6/2019 5:28:06 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/6/2019 9:25:37 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/24/2019 7:18:59 AM
argenx reports third quarter 2019 financial results and provides business update GlobeNewswire Inc. - 10/24/2019 1:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/15/2019 4:37:15 PM
argenx to Present at Morgan Stanley 17th Annual Global Healthcare Conference GlobeNewswire Inc. - 9/3/2019 1:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 8/12/2019 2:14:21 PM
argenx to Present at 2019 Wedbush PacGrow Healthcare Conference GlobeNewswire Inc. - 8/6/2019 1:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/1/2019 6:19:00 AM
argenx reports half year 2019 financial results and second quarter business update GlobeNewswire Inc. - 8/1/2019 1:00:00 AM
argenx to report half year 2019 financial results and second quarter business update on August 1, 2019 GlobeNewswire Inc. - 7/25/2019 1:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/28/2019 6:10:44 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/22/2019 6:11:23 AM
argenx announces pipeline expansion and “argenx 2021” vision to build integrated immunology company at 2019 R&D Day GlobeNewswire Inc. - 5/22/2019 1:00:00 AM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 5/9/2019 5:11:37 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/9/2019 6:52:46 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/8/2019 4:07:37 PM
riche   Wednesday, 10/17/18 04:09:07 AM
Re: None
Post # of 10 
Efgartigimod is a first-in-class antibody fragment designed for the treatment of patients with severe autoimmune diseases associated with high levels of pathogenic immunoglobulin G, or IgG, antibodies for which few innovative biologic treatments have been approved and severe unmet medical need exists. Efgartigimod has been created to degrade circulating disease-causing autoimmune antibodies and has potential in many large and orphan indications: multiple sclerosis, immune thrombocytopenia, systemic lupus erythematosus, myasthenia gravis and skin blistering



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist